<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="reviewer-report"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIRx Med</journal-id><journal-id journal-id-type="publisher-id">xmed</journal-id><journal-id journal-id-type="index">34</journal-id><journal-title>JMIRx Med</journal-title><abbrev-journal-title>JMIRx Med</abbrev-journal-title><issn pub-type="epub">2563-6316</issn></journal-meta><article-meta><article-id pub-id-type="publisher-id">57310</article-id><article-id pub-id-type="doi">10.2196/57310</article-id><title-group><article-title>Peer Review of &#x201C;Raw, Unadulterated African Honey for Ulcer Healing in Leprosy: Protocol for the Honey Experiment on Leprosy Ulcer (HELP) Randomized Controlled Trial&#x201D;</article-title></title-group><contrib-group><contrib contrib-type="author"><collab>Anonymous</collab></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Meinert</surname><given-names>Edward</given-names></name></contrib></contrib-group><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2024</year></pub-date><volume>5</volume><elocation-id>e57310</elocation-id><history><date date-type="received"><day>12</day><month>02</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>02</month><year>2024</year></date></history><copyright-statement>&#x00A9; Anonymous. Originally published in JMIRx Med (<ext-link ext-link-type="uri" xlink:href="https://med.jmirx.org">https://med.jmirx.org</ext-link>), 1.3.2024. </copyright-statement><copyright-year>2024</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://med.jmirx.org/">https://med.jmirx.org/</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://xmed.jmir.org/2024/1/e57310"/><related-article related-article-type="companion" ext-link-type="doi" xlink:href="10.1101/2023.07.14.23292603v1" xlink:title="Preprint (medRxiv)" xlink:type="simple">https://www.medrxiv.org/content/10.1101/2023.07.14.23292603v1</related-article><related-article related-article-type="companion" ext-link-type="doi" xlink:href="10.2196/56442" xlink:title="Authors' Response to Peer-Review Reports" xlink:type="simple">https://med.jmirx.org/2024/1/e56442</related-article><related-article related-article-type="companion" ext-link-type="doi" xlink:href="10.2196/50970" xlink:title="Published Article" xlink:type="simple">https://med.jmirx.org/2024/1/e50970</related-article><kwd-group><kwd>leprosy</kwd><kwd>ulcers</kwd><kwd>wounds</kwd><kwd>honey</kwd><kwd>neuropathy</kwd><kwd>nerves</kwd><kwd>Africa</kwd><kwd>randomized controlled trial</kwd><kwd>RCT</kwd></kwd-group></article-meta></front><body><p><italic>This is the peer-review report for &#x201C;Raw, Unadulterated African Honey for Ulcer Healing in Leprosy: Protocol for the Honey Experiment on Leprosy Ulcer (HELP) Randomized Controlled Trial.&#x201D;</italic></p><sec id="s2"><title>Round 1 Review</title><sec id="s1-1"><title>General Comments</title><p>This paper is a protocol description of an important study [<xref ref-type="bibr" rid="ref1">1</xref>], especially for contexts in which advanced wound care products are often not available. It is a well-written protocol with clear steps to take. Below are some of my feedback; I also included some small textual feedback points in the text. You may not be able to address all the points I raised, as it seems that the trial has already started, but in that case, it would be interesting to describe why or why not in the manuscript&#x2019;s text.</p></sec><sec id="s1-2"><title>Specific Comments</title><sec id="s1-2-1"><title>Major Comments</title><p>1. Please describe why the 84-day cutoff period was chosen.</p><p>2. The flowchart is a bit small and thus hard to read.</p><p>3. Usually, overlapping inclusion and exclusion criteria are not mentioned.</p><p>4. It is not clear why hepatitis B or C were added in the exclusion criteria list.</p><p>5. It is not clear for me if patients are clinically admitted or not, and if so, why? For how long? Is this routine care? And what are the discharge criteria?</p><p>6. If diabetes is excluded, it may be good to also exclude other known reasons for peripheral neuropathy (eg, vitamin B deficiencies)</p><p>7. Are signs of infection also monitored, assessed, or outcome measures?</p><p>8. Please explain more on the swabs: what kind of swab is it and what is tested, if this is not part of the research project? In general, it is better to take a routine swab to test for infection (bacterial growth) prior to inclusion instead of prior to randomization, as infection is an exclusion criteria. Also, address this under the heading about &#x201C;biological specimens.&#x201D;</p><p>9. Explain why the video recording is taking place. It may be interesting to also do it with the last 5 patients if it is performed for monitoring reasons.</p><p>10. Why are assessors from Nepal used and not contextual assessors from Nigeria itself (also, is it because of skin color differences of participants in both countries)?</p><p>11. Please explain why early analysis is taking place after the inclusion of the first three-eighths of participants.</p><p>12. I missed the argument in the discussion that mentioned that honey is often relatively cheap and better available than many advanced wound care products.</p><p>13. Include some information about how long data will be stored (number of years), where it will be stored in a secure way, and if it will be shared (pseudonymized) if requested (eg, for reproducibility).</p></sec><sec id="s1-2-2"><title>Minor Comments</title><p>14. Write numbers up to 9 in text.</p><p>15. Check abbreviations.</p><p>16. Update reference list, include authors, URLs and &#x201C;assessed on [date]&#x201D; in references to websites and online documents.</p><p>17. Explain the camera used for photography.</p><p>18. Please add 2 more references in the discussion.</p><p>19. Explain more about the pedometer usage.</p></sec></sec></sec></body><back><fn-group><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udo</surname><given-names>S</given-names></name><name name-style="western"><surname>Ogbu Sunday</surname><given-names>P</given-names></name><name name-style="western"><surname>Tsaku</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Raw, unadulterated African honey for ulcer healing in leprosy: protocol for the Honey Experiment on Leprosy Ulcer (HELP) randomized controlled trial</article-title><source>JMIRx Med</source><year>2024</year><volume>5</volume><fpage>e50970</fpage><pub-id pub-id-type="doi">10.2196/50970</pub-id></nlm-citation></ref></ref-list></back></article>